Pharmacogenomics in treatment of depression and psychosis: an update

被引:30
|
作者
Jukic, Marin [1 ,2 ]
Milosavljevi, Filip [1 ,2 ]
Molden, Espen [3 ,4 ]
Ingelman-Sundberg, Magnus [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, Stockholm, Sweden
[2] Univ Belgrade, Fac Pharm, Dept Physiol, Belgrade, Serbia
[3] Diakonhjemmet Hosp, Ctr Psychopharmacol, Oslo, Norway
[4] Univ Oslo, Dept Pharm, Sect Pharmacol & Pharmaceut Biosci, Oslo, Norway
基金
瑞典研究理事会; 欧洲研究理事会;
关键词
CONSENSUS GUIDELINES; IMPLEMENTATION CONSORTIUM; CONTROLLED-TRIAL; DISORDER; CYP2D6; NEUROPSYCHOPHARMACOLOGY; METAANALYSIS; REMISSION; EFFICACY; IMPACT;
D O I
10.1016/j.tips.2022.09.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.
引用
收藏
页码:1055 / 1069
页数:15
相关论文
共 50 条
  • [31] An update on prediction of treatment outcome in treatment resistant depression
    Kautzky, Alexander
    Dold, Markus
    Gryglewski, Gregor
    Baldinger-Melich, Pia
    Spies, Marie
    Vanicek, Thomas
    Souery, Daniel
    Montgomery, Stuart
    Mendlewicz, Julien
    Zohar, Joseph
    Serretti, Alessandro
    Lanzenberger, Rupert
    Kasper, Siegfried
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 77 - 77
  • [32] CLINICAL RELEVANCE OF PHARMACOGENOMICS IN DEPRESSION
    Cascorbi, Ingolf
    DRUG METABOLISM REVIEWS, 2008, 40 : 19 - 20
  • [33] Pharmacogenomics: an Update for Child and Adolescent Psychiatry
    Lisa B. Namerow
    Sophia A. Walker
    Mirela Loftus
    Jeffrey R. Bishop
    Gualberto Ruaño
    Salma Malik
    Current Psychiatry Reports, 2020, 22
  • [34] Pharmacogenomics of breast cancer therapy: An update
    Westbrook, Kelly
    Stearns, Vered
    PHARMACOLOGY & THERAPEUTICS, 2013, 139 (01) : 1 - 11
  • [35] Update on the clinical pharmacogenomics of organ transplantation
    Burckart, Gilbert J.
    Amur, Shashi
    PHARMACOGENOMICS, 2010, 11 (02) : 227 - 236
  • [36] Pharmacogenomics: an Update for Child and Adolescent Psychiatry
    Namerow, Lisa B.
    Walker, Sophia A.
    Loftus, Mirela
    Bishop, Jeffrey R.
    Ruano, Gualberto
    Malik, Salma
    CURRENT PSYCHIATRY REPORTS, 2020, 22 (05)
  • [37] Prevention and treatment of Postpartum Mania, Psychosis, and psychotic depression
    Bergink, Veerle
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2023, 74 : 92 - 94
  • [38] Treatment options for depression and psychosis in Parkinson's disease
    W. Poewe
    K. Seppi
    Journal of Neurology, 2001, 248 (Suppl 3) : 12 - 21
  • [39] DOTHIEPIN IN THE TREATMENT OF DEPRESSION OCCURRING DURING PSYCHOSIS EVOLUTION
    SECHTER, D
    DESAHB, R
    BOUDET, A
    LEUTENEGGER, E
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 1994, 20 (04): : 445 - 450
  • [40] Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease
    Voon, V
    Lang, AE
    CLINICAL NEUROPHARMACOLOGY, 2004, 27 (02) : 90 - 92